Presentation (CTI)

OBJECTIVES: This study evaluated the clinical value of testing patients with advanced/metastatic EGFR wild-type non-squamous non-small cell lung cancer (NSCLC) with MET immunohistochemistry (IHC) to identify those with high and high/intermediate c-Met protein overexpression (OE), who would then be eligible for telisotuzumab vedotin (Teliso-V), an investigational antibody-drug conjugate.
METHODS: A deterministic decision-tree (for treatment and MET IHC testing allocations) into a stochastic partition-survival model (for efficacy-related outcomes) was used to evaluate clinical utility of MET IHC testing. The model simulated patients into two cohorts: tested or not-tested. Patients with no testing received standard of care (SOC). Patients with testing and c-Met protein OE positivity received Teliso-V, while patients with c-Met low/no OE received SOC. Two scenarios, c-Met OE or c-Met high OE, were analyzed. Prevalence and clinical outcomes among patients with c-MET protein OE treated with SOC or Teliso-V were based on published literature. Efficacy inputs (ie, overall survival, progression-free survival) were estimated based on exponential survival curves derived from published clinical and real-world data. The model estimated expected and incremental life years (LYs) and quality-adjusted life years (QALYs).
RESULTS: For patients tested for c-Met protein OE, simulated patients in the tested cohort had an incremental improvement of 6154 LYs and 4363 QALYs relative to patients in the not-tested cohort, among all eligible patients in the US. Among those patients who would have tested positive for c-Met protein OE in both tested and not-tested cohorts, those in the tested cohorts had a 79.0% and 79.2% incremental improvement in LYs and QALYs, respectively. c-Met high OE analyses also demonstrated LY and QALY improvements among those tested for c-Met.
CONCLUSIONS: The model findings suggest clinical value in implementing testing for c-Met protein OE among all eligible NSCLC patients, as demonstrated by improved outcomes among patients when MET IHC testing is conducted.